

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1–12. (Canceled)

13. (New) A method for treating pathologies for which the number of antigenic sites or the antigenic density is low selected from the group consisting of hemolytic disease of the newborn, Sézary syndrome, chronic myeloid leukemias, cancers in which the antigenic targets are weakly expressed, breast cancer, pathologies associated with the environment that target in particular individuals exposed to polychlorinated biphenyls, infectious diseases, tuberculosis, chronic fatigue syndrome (CFS), parasitic infections and schistosomula, comprising administering an optimized human or humanized monoclonal antibody, wherein said antibody as a general glycan structure of the biantennary type, with short chains, a low degree of sialylation, non-intercalated terminal attachment point mannoses and GlcNAcs, and a low degree of fucosylation.

Claim 14. (New) The method according to claim 13, wherein said antibody is produced by cells of rat myeloma lines, in particular YB2/0 and its derivatives.